Spinal disorders encompass a wide range of conditions affecting the vertebral column, spinal cord, and associated structures. Several factors contribute to the increasing incidence of spinal disorders and, in turn, the demand for spinal graft materials. Modern lifestyles, which may involve prolonged sitting, reduced physical activity, and poor posture, can contribute to the development of spinal disorders. These factors can accelerate the wear and tear on spinal structures and increase the risk of conditions such as herniated discs and lumbar degeneration. Traumatic injuries, such as motor vehicle accidents, falls, and sports-related injuries, can result in spinal fractures, dislocations, and other severe spinal disorders. These injuries often necessitate surgical interventions and the use of graft materials for spinal reconstruction.
The rising incidence of spinal disorders underscores the importance of effective treatment options, including spinal grafts, to address these conditions and improve patients' quality of life.
Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-spinal-allografts-and-xenograft-market
Data Bridge Market Research analyzes that the Europe Spinal Allografts and Xenograft Market is expected to grow with a CAGR of 5.6% in the forecast period of 2023 to 2030 and is expected to reach USD 669.39 million by 2030. The Allograft segment is projected to propel the market growth due to the advancements in surgical techniques used in spinal graft.
Key Findings of the Study
Advancements in Regenerative Medicines
Regenerative medicine is a rapidly evolving field that focuses on harnessing the body's natural ability to repair and regenerate tissues. Allografts and xenografts play a crucial role in regenerative medicine by serving as graft materials for various tissue and organ repair procedures. Regenerative medicine techniques, such as tissue engineering and stem cell therapy, are advancing tissue regeneration capabilities. Allografts and xenografts are often used as scaffolds or matrices in tissue engineering applications. Their compatibility with regenerative approaches makes them valuable in achieving enhanced tissue regeneration, driving demand for these graft materials. Stem cell therapies, including Mesenchymal Stem Cell (MSC) treatments, are being used to promote tissue repair and regeneration. Allografts and xenografts can serve as carriers for stem cells, aiding their delivery and integration into damaged tissues. This synergy between graft materials and stem cell therapies offers opportunities for innovative regenerative treatments.
Advances in biomaterials and graft processing technologies have led to the development of more biocompatible and tissue-friendly graft materials. Improved biocompatibility ensures that graft materials are well-tolerated by the body, reducing the risk of complications and promoting successful tissue regeneration.
Hence, advancements in regenerative medicines are expected to provide an opportunity for market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product Type (Allograft, Xenograft, Bone Graft Supplements), Approaches (Anterior Lumbar Interbody Fusion (ALIF), Transforaminal Lumbar Interbody Fusion (TLIF), Posterior Lumbar Interbody Fusion (PLIF), Surgery Type (Open Spine Surgery and Minimally Invasive Spine Surgery), Indication (Degenerative Diseases, Spinal Trauma or Fractures, Spinal Tumors, Revision Surgeries, Spinal Infections (Osteomyelitis or Discitis), Spinal Deformities, Congenital Spinal Abnormalities, and Others), Age Group (Adult, Geriatric, and Pediatric), End User (Hospital, Speciality Clinic, Ambulatory Surgical Centers, and Others)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Russia, Switzerland, Netherlands, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway, and Rest of Europe
|
|
Market Players Covered
|
Medtronic (Ireland), Arthrex, Inc. (U.S.), Stryker (U.S.), ZimVie Inc. (U.S.), and Medical Devices Business Services, Inc. (U.S.), RTI Surgical (U.S.), Integra LifeSciences (U.S.), Orthofix US LLC. (U.S.), ATEC Spine, Inc (U.S.), Globus Medical (U.S.), Exactech, Inc. (U.S.), Regenity (U.S.), Cerapedics.Inc (U.S.), Bioventus (U.S.) and among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe spinal allografts and xenograft market is segmented into six notable segments based on product type, approaches, surgery type, indication, age group, and end user.
- On the basis of product type, the market is segmented into allograft, xenograft, and bone graft supplements.
In 2023, allograft segment is anticipated to dominate the Europe spinal allografts and xenograft market
In 2023, the allograft segment is expected to dominate the market with a market share of 63.67% due to the rising incidence of spinal disorders in Europe.
- On the basis of approaches, the market is segmented into anterior lumbar interbody fusion (ALIF), transforaminal lumbar interbody fusion (TLIF), and posterior lumbar interbody fusion (PLIF).
In 2023, anterior lumbar interbody fusion (ALIF) segment is expected to dominate the Europe spinal allografts and xenograft market
In 2023, the anterior lumbar interbody fusion (ALIF) segment is expected to dominate the market with a market share of 45.46% due to the advancements in surgical techniques used in spinal graft.
- On the basis of surgery type, the market is segmented into open spine surgery and minimally invasive spine surgery. In 2023, the open spine surgery segment is expected to dominate the market with a market share of 57.42%.
- On the basis of indication, the market is segmented into degenerative diseases, spinal trauma or fractures, spinal tumors, revision surgeries, spinal infections (osteomyelitis or discitis), spinal deformities, congenital spinal abnormalities, and others. In 2023, the degenerative diseases segment is expected to dominate the market with a market share of 38.14%.
- On the basis of age group, the market is segmented into geriatric, adult, and pediatric. In 2023, the adult segment is expected to dominate the market with a market share of 50.40%.
On the basis of end user, the market is segmented into hospital, speciality clinic, ambulatory surgical centers, and others. In 2023, the hospital segment is expected to dominate the market with a market share of 48.80%.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the Europe Spinal Allografts and Xenograft Market are Medtronic (Ireland), Arthrex, Inc. (U.S.), Stryker (U.S.), ZimVie Inc. (U.S.), Medical Devices Business Services, Inc. (U.S.) and among others.
Market Development
- In September 2023, Globus Medical announced that it had completed its previously announced merger with NuVasive, Inc. The combined company will provide surgeons and patients with one of the most comprehensive offerings of musculoskeletal procedural solutions and enabling technologies to impact the care continuum.
- In August 2023, ZimVie Inc. announced the expansion of its cooperation agreement with BRAINLAB for global co-marketing purposes. This will help the organization in developing annual revenue. In July 2022, AbbVie and iSTAR Medical SA announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. The deal strengthens its capabilities to develop and manufacture Glaucoma surgery products for its customers for use in minimally invasive procedures.
- In July 2023, Cerapedics.Inc. announced the expansion of its headquarters in the Denver metro area to support the growth of its products, which include the U.S. Food and Drug Administration (FDA)-approved i-FACTOR bone graft for cervical spinal fusion and its next-generation product currently being evaluated for lumbar spinal fusion. This will increase the company annual revenue.
- In January 2023, Orthofix US LLC. and SeaSpine Holdings Corporation announced the successful completion of their previously announced merger. This will help the organization develop a brand image among others.
- In July 2021, RTI Surgical, a leading surgical implant company providing blue-chip OEM customers with a portfolio of tissue-based synthetic and metal implants, entered into a long-term strategic agreement with leading global medical device OEM Exactech, related to the development and supply of biologic bone substitutes.
Regional Analysis
Geographically, the countries covered in the Europe spinal allografts and xenograft market report are Germany, France, U.K., Italy, Spain, Russia, Switzerland, Netherlands, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway, and Rest of Europe.
As per Data Bridge Market Research analysis:
Germany is the dominant and fastest country in Europe spinal allografts and xenograft market during the forecast period 2023 - 2030.
Germany is expected to dominate and fastest growing country due to high technological advancement and growing market players presence in the country.
For more detailed information about the Europe spinal allografts and xenograft market report, click here – https://www.databridgemarketresearch.com/reports/europe-spinal-allografts-and-xenograft-market
